Clevidipine Infusion for Blood Pressure Management After Successful Revascularization in Acute Ischemic Stroke

Launched by PROMEDICA HEALTH SYSTEM · Dec 14, 2021

Keywords

ClinConnect Summary

The CLEVER Study is examining how effectively a medication called Clevidipine can help manage high blood pressure in patients who have had a stroke and undergone a procedure called mechanical thrombectomy to remove a blood clot. This trial is specifically looking at patients who have just experienced an acute ischemic stroke, which is when blood flow to the brain is blocked. The goal is to see if controlling blood pressure closely with Clevidipine can improve patient outcomes after the procedure.

To participate in this study, individuals must be at least 18 years old and have high blood pressure at the time of treatment. They should have specific types of strokes confirmed by imaging tests and have had successful restoration of blood flow during the procedure. Participants will be closely monitored and will need to provide consent shortly after their treatment. This trial is currently recruiting participants and aims to gather important information that could help improve care for stroke patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age 18 or older
• • 2. Acute hypertension (systolic blood pressure of greater than 140 mmHg) at recanalization
• • 3. Anterior circulation ischemic stroke symptoms and confirmed occlusion (ICA, M1, or M2) on angiogram with mechanical thrombectomy initiated within 24 hours since last known well
• • 4. Success revascularization score of mTICI 2c or higher after mechanical thrombectomy
• • 5. ASPECTS score of greater than 6
• • 6. Premorbid mRS 0-4
• • 7. Signed informed consent within 30 minutes from end of MT procedure.
• Exclusion Criteria:
• • 1. Presence of any hemorrhage and/or ASPECT score ≤6 on baseline head CT scan
• • 2. Pregnant or lactating
• • 3. Acute traumatic brain injury
• • 4. Patient on active dialysis
• • 5. Intracranial neoplasm
• • 6. Acute or recent STEMI in the last 30 days
• • 7. Severe arrhythmias, unstable cardiac function
• • 8. Any terminal medical condition with life expectancy less than 6 months
• • 9. Concurrent enrollment in another trial that could confound the results of this study